Wells Fargo analyst Stephen Baxter raised the firm’s price target on Elevance Health (ELV) to $412 from $330 and keeps an Overweight rating on the shares. The firm is updating estimates and price targets in the space ahead of Q3 2025 results. Notability, Wells now assumes extension of enhanced subsidies is likely.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Trade: White House announces drug pricing deal with Pfizer
- Health Insurance subsidies central to government shutdown negotiation, WSJ says
- Trump says working on reducing cost of health insurance
- Elevance Health Issues New Series of Notes